Benjamin Click, MD: Biosimilars in IBD

Benjamin Click, MD, staff gastroenterologist, the Cleveland Clinic, discusses how biosimilars fit in the treatment paradigm for inflammatory bowel disease (IBD). 
October 07, 2019


Yes, so I think biosimilars have the opportunity to potentially change the biologic landscape. Biosimilars are just starting to come into routine clinical practice in the United States. They’ve been used for several more years in European and non-American countries, so a lot of the more long-term experience coming from the European colleagues is very encouraging.

We are starting to routinely use biosimilars, mostly for infliximab at this point in time, though we do hope to see a biosimilar for adalimumab hit the market in the next several years. So I think there’s a lot of potential cost savings opportunity when we think about healthcare costs in the United States and how we can potentially impact those as well.


Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.